MO - Altria Group, Inc.
42.72 0.00 (0.00%)
After hours: 6:09PM EDT
| Previous Close | 42.57 |
| Open | 42.52 |
| Bid | 42.62 x 1400 |
| Ask | 42.63 x 1400 |
| Day's Range | 42.38 - 42.80 |
| 52 Week Range | 39.30 - 66.04 |
| Volume | 6,059,505 |
| Avg. Volume | 11,244,614 |
| Market Cap | 79.805B |
| Beta (3Y Monthly) | 0.37 |
| PE Ratio (TTM) | 12.76 |
| EPS (TTM) | 3.35 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | 3.36 (7.89%) |
| Ex-Dividend Date | 2019-09-13 |
| 1y Target Est | 53.50 |
- Zacks
Altria (MO) Gains As Market Dips: What You Should Know
Altria (MO) closed the most recent trading day at $42.73, moving +0.38% from the previous trading session.
- GlobeNewswire
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Against Altria Group, Inc.– MO
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Altria Group, Inc. (MO) from December 20, 2018 through September 24, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Slack Technologies, Inc. investors under the federal securities laws. To join the class action, go http://pawarlawgroup.com/cases/altria-group-inc/ or call Vik Pawar, Esq.
- Newsfile
ALTRIA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Altria Group, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - October 14, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Altria Group, Inc. (NYSE: MO) ("Altria" or the "Company") of the December 2, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi logoCannot view this image? Visit:https://orders.newsfilecorp.com/files/6455/48740_5f704ba6446cc9dd_logo_lg.jpgIf you invested in Altria stock or options ...
- ACCESSWIRE
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Altria Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 14, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altria Group, Inc. ("Altria" or "the Company") (NYSE:MO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- Business Wire
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altria Group, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming December 2, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Altria Group, Inc. (“Altria” or the “Company”) (NYSE: MO) securities between December 20, 2018 and September 24, 2019, inclusive (the “Class Period”). Investors suffering losses on their Altria investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- Insider Monkey
8 Lowest Tar and Nicotine Cigarette Brands in 2019
For those looking for a milder taste and lighter effect of a cigarette, we prepared a list of lowest tar and nicotine cigarette brands in 2019. Let’s start off with some crude facts. A cigarette consists of around 600 ingredients, which contain more than 7000 chemicals, of which 4,000 to 5,000 are harmful. Tar and nicotine are only two […]
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of TXT, MO and MYGN
NEW YORK, NY / ACCESSWIRE / October 13, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- ACCESSWIRE
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Altria Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 10, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altria Group, Inc. ("Altria" or "the Company") (NYSE:MO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- GlobeNewswire
SHAREHOLDER ALERT: CLAIMSFILER REMINDS MO, MTCH, RUHN, SDC INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
NEW ORLEANS, Oct. 11, 2019 -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.
- TheStreet.com
5 Dividend Kings for the Coming Storm
These five stocks have shared more than 60 consecutive annual dividend increases with their respective shareholders and their current dividend yields are greater than that for the S&P; 500.
- ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altria Group, Inc. of Class Action Lawsuit and Upcoming Deadline - MO
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Pomerantz LLP announces that a class action lawsuit has been filed against Altria Group, Inc. ("Altria" or the "Company") (MO) and certain of its officers. The class action, filed in United States District Court, for the Eastern District of New York, and indexed under 19-cv-05579, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Altria securities between December 20, 2018 and September 24, 2019, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- ACCESSWIRE
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of DBX, MO and MYGN
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Investors Affected: on behalf of all persons who purchased Dropbox Class A common stock pursuant or traceable to the registration statement issued in connection with the Company’s March 23, 2018 initial public offering.
- GlobeNewswire
INVESTOR ALERT - Altria Group, Inc. (MO) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: December 2, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Altria Group, Inc. (“Altria” or the “Company”) (NYSE: MO) and certain of its officers, on behalf of shareholders who purchased Altria securities between February 8, 2019 and August 12, 2019, both dates inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
- ACCESSWIRE
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MO, MTCH and CVET
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- Business Wire
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altria Group, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 2, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Altria Group, Inc. (“Altria” or the “Company”) (NYSE: MO) investors who purchased securities between December 20, 2018 and September 24, 2019, inclusive (the “Class Period”). If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On December 20, 2018, Altria acquired a 35% stake in investment in JUUL Labs, Inc. (“JUUL”), the purported U.S. leader in electronic vapor products, including e-cigarettes.
- ACCESSWIRE
CLASS ACTION UPDATE for VAL, MO and CVET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...
- ACCESSWIRE
SHAREHOLDER ALERT - Altria Group, Inc. (MO) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: December 2, 2019
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Altria Group, Inc. ("Altria" or the "Company") ...
- InvestorPlace
Altria’s Juul Labs Investment Not Looking So Hot
Fitch credit analysts, Bill Densmore and Carla Norfleet Taylor, wrote in a note Oct. 8 that they believe Altria (NYSE:MO) will have to write down the value of its 35% stake in Juul Labs in light of the vaping scandal gripping the nation. Needless to say, if you own Altria stock, you're more than a little concerned about the company's $12.8 billion investment in Juul. Source: Kristi Blokhin / Shutterstock.com InvestorPlace - Stock Market News, Stock Advice & Trading TipsOn Oct. 4, the Wall Street Journal reported that Darsana Capital Partners, a New York City-based hedge fund, recently wrote down its investment in Juul Labs, giving it a valuation of $24 billion, down from its $38 billion value in December 2018. A quick piece of math tells me that Altria's investment in Juul is now worth $8.4 billion, $4.4 billion less than what it paid at the end of 2018. With Juul's investment looking less than stellar, the cigarette maker's investment in Cronos Group (NASDAQ:CRON) isn't looking nearly as bad. Here's why that's a good thing. Altria Got a BargainIn my most recent article about why Altria's investment in Cronos was positive for CRON stock, I gave readers three reasons why I thought it made sense. Now, as the vaping scandal seems to be intensifying, I wonder whether Altria's brain trust spent enough time thinking about the downside of its e-cigarette investment."Altria would not have made a $12.8 billion investment in Juul Labs or a $1.8 billion investment in CRON stock if it didn't understand the health risks associated with vaping. MO has been down this road many times with cigarettes," I wrote in September. As credit analysts and professional investors second guess the value of Juul Labs, it's clear that Atria's investment in the maker of e-cigarettes isn't nearly as much of a slam dunk as it thought it was when it closed the deal last December. Meanwhile, Cronos stock has also faced a headwind due to the fact that it's focusing its growth on vaping. CRON stock lost 18% of its value in September as investors questioned how much vaping-related sales would grow under the current regulatory haze. While I believe that regulators will ultimately get this entire health scare sorted and both Juul and Cronos will go back to running their businesses, I can't help but think how relieved Altria's management must be that they made the $1.8 billion investment in Cronos in exchange for 45% of its stock. The Upside to Altria StockAt the end of December 2018, not too long after Altria closed its investments on both Juul and Cronos, I wrote a piece entitled "Compared to Juul Labs, Altria Got a Steal in Cronos Stock." Eight months later, if anything, Altria's investment in Cronos is looking like a lifesaver. "While Cronos doesn't have anywhere near $1.5 billion in revenue -- the cannabis company had just CAD$3.8 million in its most recent quarter -- it gives Altria a platform for growth in a market that's destined to be much bigger on a global basis than e-cigs could ever hope to be," I wrote in December of last year. Forget the fact that Cronos is focusing its growth on vaping for a moment and consider that Altria gained control of a large player in the cannabis game for just $2.9 billion, including the $1.1 billion to exercise the additional 10% that takes its stake to 55%. When Altria acquired its 45% stake, Cronos had a market cap of approximately $4 billion. Today, it's around $2.9 billion, which means Altria's sitting on a $500 million unrealized loss from Cronos. That could turn out to be a bargain because Cronos is sitting on more than a $1 billion of Altria's cash. If the vaping crisis goes on for months or years, Cronos has enough cash to ride out the vaping scare while producing and selling a decent amount of dried flower. It might not be a top-tier cannabis producer, but it's got access to every market in Canada. And with Altria's help, it will flourish south of the border once federal legalization happens. In addition, if cannabis stocks suffer under the weight of the vaping scandal, Cronos could also pick up some quality assets on the cheap. The Bottom Line on MO Stock The Altria stock price is down 12% year to date, including dividends, and 31% over the past year. The Juul controversy is not going to help it get out of the funk it's in. Nor, I'm afraid, will its investment in Cronos. But fear not, once the health issues get solved and officials know what's causing all the illnesses, both Juul and Cronos can adjust their businesses accordingly. In the meantime, Altria can focus on the 2020 rollout of IQOS across the U.S.MO stock might be down, but I don't think it's out. Not by a long shot. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Super Boring Stocks to Buy With Super Safe Returns * 10 Winning Stocks to Buy and Stick With for the Long Haul * Don't Give Up on These 4 Cannabis Stocks The post Altriaas Juul Labs Investment Not Looking So Hot appeared first on InvestorPlace.
- ACCESSWIRE
SHAREHOLDER ALERT: VAL MGNX MO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 10, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ...
- PR Newswire
Lifshitz & Miller LLP Announces Investigation of Altria Group, Inc., Chardan Healthcare Acquisition Corporation, Premier, Inc., Restoration Robotics, Inc., Vivint Solar, Inc., Waitr Holdings Inc., Xilinx, Inc., and Zscaler, Inc.
NEW YORK , Oct. 10, 2019 /PRNewswire/ -- Altria Group, Inc. (MO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that MO conducted insufficient ...
- ACCESSWIRE
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Altria Group, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 10, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Altria Group, Inc. ("Altria" or "the Company") (NYSE:MO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- InvestorPlace
CRON Stock Still a Falling Knife Without a Catalyst
The market seems to have decided that cannabis stocks like Cronos Group (NASDAQ:CRON) were in a bubble. Pot stocks have been absolutely hammered for the last few months, and Cronos Group stock has been no exception. CRON stock has dropped nearly two-thirds from its 52-week high, and now trades at 2019 lows.Source: Shutterstock Again, CRON isn't the only cannabis play taking a beating. Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), and Tilray (NASDAQ:TLRY) all are down at least 62% from 52-week highs.That obviously doesn't mean the sector is headed to zero. Presumably, at some point, buyers will step in. There's still a long-term opportunity in cannabis, even if early results in Canada look disappointing. Valuations clearly got out of hand, but at least on an EV/revenue basis are starting to come in.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the problem for Cronos Group stock in the near-term still holds. As I wrote in May, the company still hasn't given investors a coherent narrative for actually owning CRON stock. The best thesis I've come up with is that Cronos stock is the cannabis play for investors who believe cannabis plays are overvalued.That might well be wise long-term -- I largely agree with the strategy so far -- but it's not going to help much any time soon. With a chart that is a textbook 'falling knife' and profitability still years out, there's not much reason to predict a bottom in CRON stock just yet. The Problem With CRON Stock"Now, we understand that many investors are modeling cannabis companies off of their production capacity. However, our business model is not to be the farmer."That quote comes from Cronos CEO Mike Gorenstein on the Q2 conference call in August. And it highlights the near-term problem for Cronos Group stock.Any investor trying to time the bottom here in cannabis stocks has to believe that the sell-off has gone too far. That investor may well believe that past highs -- $20+ for CRON, $50+ for CGC, etc. -- were too high. But the thesis would be that what began as a reasonable correction to valuations has turned into a stampede of selling that ignores the broader opportunity.If that investor wants to buy a cannabis stock right now, it's exceedingly difficult for them to choose CRON. If the opportunity long-term still is intact, the play is to go with Canopy or Aurora, two companies who are aggressively going after multiple markets in the industry.As Gorenstein noted, many of those investors are valuing pot stocks off production and/or revenue. Because of its disinterest in developing production capacity, CRON stock screens poorly on both metrics (at least on a relative basis).Even after acquiring Redwood, the company does have US$1.5 billion in cash on its balance sheet -- almost half a current market capitalization of US$3.2 billion -- but that hardly makes Cronos Group stock a value play. CRON still trades at 11x EV/revenue using 2020 consensus estimates.Profitability remains several quarters out, too. Fundamentally, this is a stock that lacks a story and a catalyst. Without either, it's tough to project a near-term rally. The Long-Term Case for Cronos Group StockTo be clear, these are short-term issues. Cronos Group's cash balance gives the company time to execute its strategy. And I still believe that strategy is wise. It's an echo of what its largest shareholder, tobacco giant Altria (NYSE:MO), has done. Let farmers farm while the processor uses capital for branding, development, and distribution in higher-margin end markets.With oversupply concerns already rampant, it's somewhat surprising that Cronos Group hasn't received a little more credit for that strategy. But it hasn't, and it's possible it won't until it proves itself.And even in a best-case scenario, that's going to take some time. In the meantime, the chart is ugly, the sector is collapsing, and there aren't any external catalysts on the horizon.The U.S. House of Representatives did pass the SAFE Banking Act, a presumed step toward potential legalization. Last year, such a development likely would have sent cannabis stocks soaring. This year, it barely registered: the sector-wide sell-off has continued.Investors need to look at that price action for all cannabis stocks, but especially CRON. It's not going to bottom before its sector does. And given its strategy, it's likely going to be late in joining any rally. The long-term strategy is intriguing, and valuation is getting at least palatable. Still, there's absolutely no need to rush.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Super Boring Stocks to Buy With Super Safe Returns * 10 Winning Stocks to Buy and Stick With for the Long Haul * Don't Give Up on These 4 Cannabis Stocks The post CRON Stock Still a Falling Knife Without a Catalyst appeared first on InvestorPlace.
- Yahoo Finance Video
Researcher explains how e-cigarette smoke is linked to lung cancer in mice
The CDC says the total cases of vaping-related illnesses rose to nearly 1,300 incidents, and at least 26 confirmed deaths. Yahoo Finance's Zack Guzman & Julia La Roche, along with CapitalistBook.com author Nathan Latka discuss with NYU School of Medicine's Moon-Shong Tang.
